Clinical Trials
41 trialsSTIM 2
University Hospital, Bordeaux
ASC4INDIA
Novartis
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
National Institutes of Health Clinical Center (CC)
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Novartis
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
ACALLO
Polish Lymphoma Research Group
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd.
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Kyowa Kirin Co., Ltd.
SIMPly-CARE
Rigshospitalet, Denmark
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Fate Therapeutics
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
Genentech, Inc.
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Alexion Pharmaceuticals, Inc.
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
DIALOG
Novartis
Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy
University of Milano Bicocca
Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)
Celgene
RESONATEâ„¢
Pharmacyclics LLC.
GAH
Celgene
OCEAN
Celgene
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Novartis
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
WIN
University Hospital Southampton NHS Foundation Trust
SPIRIT2
Newcastle University
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
National Institutes of Health Clinical Center (CC)
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
GlaxoSmithKline
An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
Hoffmann-La Roche
Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
Hoffmann-La Roche
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
University of Pittsburgh
LASOR
Novartis
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Mirati Therapeutics Inc.
Rituximab for Prevention of Chronic GVHD
Dana-Farber Cancer Institute
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Sanofi
Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance
Hospital Universitario Dr. Jose E. Gonzalez
STIM
University Hospital, Bordeaux
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
Pharmacyclics LLC.
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia
Genta Incorporated
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
Bristol-Myers Squibb
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia
Genta Incorporated
Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children
Ann & Robert H Lurie Children's Hospital of Chicago